Carson Advisory Inc. Buys 808 Shares of Illumina, Inc. (NASDAQ:ILMN)

Carson Advisory Inc. increased its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 29.3% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,565 shares of the life sciences company’s stock after buying an additional 808 shares during the quarter. Carson Advisory Inc.’s holdings in Illumina were worth $283,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of the stock. Diversified Trust Co bought a new position in Illumina in the 1st quarter valued at $355,000. State of Alaska Department of Revenue grew its stake in shares of Illumina by 2.5% during the 1st quarter. State of Alaska Department of Revenue now owns 18,527 shares of the life sciences company’s stock worth $1,469,000 after acquiring an additional 445 shares during the period. Merit Financial Group LLC grew its stake in shares of Illumina by 344.8% during the 1st quarter. Merit Financial Group LLC now owns 13,036 shares of the life sciences company’s stock worth $1,034,000 after acquiring an additional 10,105 shares during the period. Trexquant Investment LP grew its stake in shares of Illumina by 16.7% during the 4th quarter. Trexquant Investment LP now owns 142,977 shares of the life sciences company’s stock worth $19,106,000 after acquiring an additional 20,506 shares during the period. Finally, Robeco Institutional Asset Management B.V. grew its stake in shares of Illumina by 15.1% during the 1st quarter. Robeco Institutional Asset Management B.V. now owns 516,293 shares of the life sciences company’s stock worth $40,963,000 after acquiring an additional 67,676 shares during the period. Institutional investors own 89.42% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently weighed in on the company. Guggenheim cut their price target on Illumina from $122.00 to $114.00 and set a “buy” rating for the company in a research note on Friday, May 9th. Barclays reissued an “underweight” rating and set a $85.00 price objective (up previously from $77.00) on shares of Illumina in a report on Tuesday, June 24th. Royal Bank Of Canada dropped their price objective on Illumina from $128.00 to $112.00 and set an “outperform” rating on the stock in a report on Tuesday, April 8th. Piper Sandler dropped their price objective on Illumina from $190.00 to $185.00 and set an “overweight” rating on the stock in a report on Thursday, May 15th. Finally, Morgan Stanley dropped their price objective on Illumina from $136.00 to $100.00 and set an “equal weight” rating on the stock in a report on Monday, May 12th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $125.11.

Insider Buying and Selling at Illumina

In other news, CFO Ankur Dhingra bought 6,100 shares of Illumina stock in a transaction that occurred on Monday, May 12th. The stock was bought at an average price of $81.21 per share, for a total transaction of $495,381.00. Following the purchase, the chief financial officer directly owned 24,906 shares of the company’s stock, valued at approximately $2,022,616.26. The trade was a 32.44% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 2.60% of the stock is owned by insiders.

Illumina Stock Up 1.0%

Shares of NASDAQ:ILMN opened at $97.93 on Friday. The company has a quick ratio of 1.48, a current ratio of 1.86 and a debt-to-equity ratio of 0.63. The stock has a market cap of $15.50 billion, a P/E ratio of -16.13, a price-to-earnings-growth ratio of 1.90 and a beta of 1.36. The business’s 50 day moving average is $88.82 and its 200 day moving average is $95.45. Illumina, Inc. has a 52-week low of $68.70 and a 52-week high of $156.66.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, May 8th. The life sciences company reported $0.97 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.96 by $0.01. The business had revenue of $1.04 billion for the quarter, compared to analysts’ expectations of $1.03 billion. Illumina had a positive return on equity of 25.54% and a negative net margin of 22.25%. The business’s revenue for the quarter was down 1.4% on a year-over-year basis. During the same quarter last year, the firm earned $0.98 EPS. Sell-side analysts predict that Illumina, Inc. will post 4.51 EPS for the current year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.